CHHiP
CHHiP showed that four weeks of prostate radiotherapy in 3 Gy fractions is as effective as seven and a half weeks of conventional treatment, and 60 Gy in 20 fractions became the standard of care.
Overview
CHHiP randomised 3,216 men with localised prostate cancer to 74 Gy in 37 fractions, 60 Gy in 20 or 57 Gy in 19, delivered with intensity-modulated radiotherapy and short-course hormone therapy. Five-year biochemical or clinical failure-free survival was 88.3 percent with 74 Gy and 90.6 percent with 60 Gy, proving non-inferiority; 57 Gy did not. Late bowel and bladder effects were similar (Dearnaley and colleagues, Lancet Oncology 2016), and the 60 Gy schedule was adopted internationally.
- 90.6 vs 88.3 out of 100 alive at 5 years with 60 Gy in 20 fractions compared with 74 Gy in 37 fractions; 2.3 more per 100.
- Roughly one extra person helped for every 43 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Localised prostate cancer: 60 Gy in 20 fractions or 57 Gy in 19 versus 74 Gy in 37 fractions, all with IMRT. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
3,216 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Biochemical or clinical failure-free survival at 5 yearsprimary | 60 Gy in 20 fractions | 1,074 | 90.6% | - | - | - |
| 74 Gy in 37 fractions | 1,065 | 88.3% |
Similar pages
not linked directly; found by shared links- TrialSTART-B (UK Standardisation of Breast Radiotherapy)
Shares Alpha/beta ratio, Hypofractionated radiotherapy, Hypofractionation (fewer, larger radiotherapy doses), IMRT / IGRT (modern external beam) and the tag radiation-wave2.
- TrialFAST-Forward
Shares Hypofractionated radiotherapy, Hypofractionation (fewer, larger radiotherapy doses), IMRT / IGRT (modern external beam) and the tag radiation-wave2.
- TrialHYPO-RT-PC
Shares Hypofractionated radiotherapy, Prostate cancer and the tag radiation-wave2.
- TrialPACE-B
Shares Hypofractionated radiotherapy, Prostate cancer and the tag radiation-wave2.
- TrialIMPORT LOW
Shares Hypofractionated radiotherapy, IMRT / IGRT (modern external beam) and the tag radiation-wave2.
- TrialPRIME II
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.
- TrialCALGB 9343
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.
- TrialCATNON (EORTC 26053-22054)
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.